J Korean Assoc Oral Maxillofac Surg.  2021 Apr;47(2):76-81. 10.5125/jkaoms.2021.47.2.76.

Primary malignant mucosal melanoma of the maxillofacial area

Affiliations
  • 1Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Korea
  • 2Oral Oncology Clinic, Research Institute and Hospital, National Cancer Center, Goyang, Korea

Abstract


Objectives
We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemiology and principles of current treatments.
Materials and Methods
Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University Dental Hospital. The patients’ clinical information was reviewed retrospectively.
Results
Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recurrence rate of 75% and a metastasis rate of 65%.
Conclusion
The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection. Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to patients in reported keynote studies.

Keyword

Malignant melanoma; Immunotherapy; Oral cancer
Full Text Links
  • JKAOMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error